Department of Surgical Oncology, Health Sciences University, Gazi Yaşargil Training and Research Hospital, Diyarbakır.
Department of Surgical Oncology, Ankara University Faculty of Medicine, Ankara. Turkey.
Cir Cir. 2023;91(1):1-8. doi: 10.24875/CIRU.22000043.
This study aimed to examine the prognostic significance of the KI-67 proliferation index, especially in breast cancer (BC) patients without HER-2 expression and no nodal involvement.
The database of hormone-receptor-positive patients who underwent surgery for BC in our Surgical Oncology Clinic between 2008 and 2020 was retrospectively reviewed and recorded. Patients were categorized based on their KI-67 level, considering the cutoff value of 20%.
Our study revealed that tumors with high KI-67 levels were more likely to have a more advanced histological grade (p = 0.00) and size (p = 0.038). In the univariant analysis, KI-67 level was effective on overall survival (p = 0.044) and disease-free survival (p = 0.048). However, we found that there was no independent prognostic factor in the multivariant analysis.
Although the Ki-67 proliferation index does not yet have an agreed threshold value and scoring methodology, it can also be used to determine prognosis and evaluate treatment response in some patients.
本研究旨在探讨 Ki-67 增殖指数的预后意义,特别是在无 HER-2 表达且无淋巴结受累的乳腺癌(BC)患者中。
回顾性分析了 2008 年至 2020 年间在我们外科肿瘤诊所接受 BC 手术的激素受体阳性患者的数据库,并进行了记录。根据 KI-67 水平对患者进行分类,考虑 20%的截断值。
我们的研究表明,高 KI-67 水平的肿瘤更有可能具有更高的组织学分级(p=0.00)和更大的肿瘤大小(p=0.038)。在单变量分析中,KI-67 水平对总生存率(p=0.044)和无病生存率(p=0.048)有影响。然而,我们发现多变量分析中没有独立的预后因素。
尽管 Ki-67 增殖指数尚未有一个公认的阈值和评分方法,但它也可以用于确定某些患者的预后并评估治疗反应。